Exendin-4 Protects Against Sulfonylurea-Induced β-Cell Apoptosis
Sulfonylurea is one of the commonly used anti-diabetic drugs that stimulate insulin secretion from β-cells. Despite their glucose lowering effects in type 2 diabetes mellitus, long-term treatment brought on secondary failure characterized by β-cell exhaustion and apoptosis. ER stress induced by Ca2+...
Saved in:
Published in | Journal of Pharmacological Sciences Vol. 118; no. 1; pp. 65 - 74 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Japan
Elsevier B.V
2012
The Japanese Pharmacological Society Elsevier |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Sulfonylurea is one of the commonly used anti-diabetic drugs that stimulate insulin secretion from β-cells. Despite their glucose lowering effects in type 2 diabetes mellitus, long-term treatment brought on secondary failure characterized by β-cell exhaustion and apoptosis. ER stress induced by Ca2+ depletion in endoplasmic reticulum (ER) is speculated be one of the causes of secondary failure, but it remains unclear. Glucagon like peptide-1 (GLP-1) has anti-apoptotic effects in β-cells after the induction of oxidative and ER stress. In this study, we examined the antiapoptotic action of a GLP-1 analogue in β-cell lines and islets against ER stress induced by chronic treatment of sulfonylurea. HIT-T15 and dispersed islet cells were exposed to glibenclamide for 48 h, and apoptosis was evaluated using Annexin/PI flow cytometry. Expression of the ER stress–related molecules and sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) 2/3 was determined by real-time PCR and western blot analysis. Chronic exposure to glibenclamide increased apoptosis by depletion of ER Ca2+ concentration through reduced expression of SERCA 2/3. Pretreatment with Exendin-4 had an anti-apoptotic role through ER stress modulation and ER Ca2+ replenishing by SERCA restoration. These findings will further the understanding of one cause of glibenclamide-induced β-cell loss and therapeutic availability of GLP-1–based drugs in secondary failure by sulfonylurea during treatment of diabetes. |
---|---|
AbstractList | Sulfonylurea is one of the commonly used anti-diabetic drugs that stimulate insulin secretion from β-cells. Despite their glucose lowering effects in type 2 diabetes mellitus, long-term treatment brought on secondary failure characterized by β-cell exhaustion and apoptosis. ER stress induced by Ca(2+) depletion in endoplasmic reticulum (ER) is speculated be one of the causes of secondary failure, but it remains unclear. Glucagon like peptide-1 (GLP-1) has anti-apoptotic effects in β-cells after the induction of oxidative and ER stress. In this study, we examined the anti-apoptotic action of a GLP-1 analogue in β-cell lines and islets against ER stress induced by chronic treatment of sulfonylurea. HIT-T15 and dispersed islet cells were exposed to glibenclamide for 48 h, and apoptosis was evaluated using Annexin/PI flow cytometry. Expression of the ER stress-related molecules and sarco/endoplasmic reticulum Ca(2+)-ATPase (SERCA) 2/3 was determined by real-time PCR and western blot analysis. Chronic exposure to glibenclamide increased apoptosis by depletion of ER Ca(2+) concentration through reduced expression of SERCA 2/3. Pretreatment with Exendin-4 had an anti-apoptotic role through ER stress modulation and ER Ca(2+) replenishing by SERCA restoration. These findings will further the understanding of one cause of glibenclamide-induced β-cell loss and therapeutic availability of GLP-1-based drugs in secondary failure by sulfonylurea during treatment of diabetes. Sulfonylurea is one of the commonly used anti-diabetic drugs that stimulate insulin secretion from β-cells. Despite their glucose lowering effects in type 2 diabetes mellitus, long-term treatment brought on secondary failure characterized by β-cell exhaustion and apoptosis. ER stress induced by Ca2+ depletion in endoplasmic reticulum (ER) is speculated be one of the causes of secondary failure, but it remains unclear. Glucagon like peptide-1 (GLP-1) has anti-apoptotic effects in β-cells after the induction of oxidative and ER stress. In this study, we examined the anti-apoptotic action of a GLP-1 analogue in β-cell lines and islets against ER stress induced by chronic treatment of sulfonylurea. HIT-T15 and dispersed islet cells were exposed to glibenclamide for 48 h, and apoptosis was evaluated using Annexin/PI flow cytometry. Expression of the ER stress–related molecules and sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) 2/3 was determined by real-time PCR and western blot analysis. Chronic exposure to glibenclamide increased apoptosis by depletion of ER Ca2+ concentration through reduced expression of SERCA 2/3. Pretreatment with Exendin-4 had an anti-apoptotic role through ER stress modulation and ER Ca2+ replenishing by SERCA restoration. These findings will further the understanding of one cause of glibenclamide-induced β-cell loss and therapeutic availability of GLP-1–based drugs in secondary failure by sulfonylurea during treatment of diabetes. Sulfonylurea is one of the commonly used anti-diabetic drugs that stimulate insulin secretion from β-cells. Despite their glucose lowering effects in type 2 diabetes mellitus, long-term treatment brought on secondary failure characterized by β-cell exhaustion and apoptosis. ER stress induced by Ca2+ depletion in endoplasmic reticulum (ER) is speculated be one of the causes of secondary failure, but it remains unclear. Glucagon like peptide-1 (GLP-1) has anti-apoptotic effects in β-cells after the induction of oxidative and ER stress. In this study, we examined the antiapoptotic action of a GLP-1 analogue in β-cell lines and islets against ER stress induced by chronic treatment of sulfonylurea. HIT-T15 and dispersed islet cells were exposed to glibenclamide for 48 h, and apoptosis was evaluated using Annexin/PI flow cytometry. Expression of the ER stress–related molecules and sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) 2/3 was determined by real-time PCR and western blot analysis. Chronic exposure to glibenclamide increased apoptosis by depletion of ER Ca2+ concentration through reduced expression of SERCA 2/3. Pretreatment with Exendin-4 had an anti-apoptotic role through ER stress modulation and ER Ca2+ replenishing by SERCA restoration. These findings will further the understanding of one cause of glibenclamide-induced β-cell loss and therapeutic availability of GLP-1–based drugs in secondary failure by sulfonylurea during treatment of diabetes. Keywords:: endoplasmic reticulum (ER) calcium depletion, apoptosis, ER stress, glucagon like peptide-1(GLP-1), sulfonylurea Sulfonylurea is one of the commonly used anti-diabetic drugs that stimulate insulin secretion from β-cells. Despite their glucose lowering effects in type 2 diabetes mellitus, long-term treatment brought on secondary failure characterized by β-cell exhaustion and apoptosis. ER stress induced by Ca2+ depletion in endoplasmic reticulum (ER) is speculated be one of the causes of secondary failure, but it remains unclear. Glucagon like peptide-1 (GLP-1) has anti-apoptotic effects in β-cells after the induction of oxidative and ER stress. In this study, we examined the antiapoptotic action of a GLP-1 analogue in β-cell lines and islets against ER stress induced by chronic treatment of sulfonylurea. HIT-T15 and dispersed islet cells were exposed to glibenclamide for 48 h, and apoptosis was evaluated using Annexin/PI flow cytometry. Expression of the ER stress–related molecules and sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) 2/3 was determined by real-time PCR and western blot analysis. Chronic exposure to glibenclamide increased apoptosis by depletion of ER Ca2+ concentration through reduced expression of SERCA 2/3. Pretreatment with Exendin-4 had an anti-apoptotic role through ER stress modulation and ER Ca2+ replenishing by SERCA restoration. These findings will further the understanding of one cause of glibenclamide-induced β-cell loss and therapeutic availability of GLP-1–based drugs in secondary failure by sulfonylurea during treatment of diabetes. |
Author | Lim, Dong-Mee Park, Hyung-Seo Park, Keun-Young Choi, Kyung-Jin Kim, Ju-Young Moon, Chan-Il Kim, Byung-Joon Lee, Seong-Kyu Baik, Haing-Woon |
Author_xml | – sequence: 1 givenname: Ju-Young surname: Kim fullname: Kim, Ju-Young organization: Division of Endocrinology and Metabolism, Department of Internal Medicine, Daejeon 302-832, Korea – sequence: 2 givenname: Dong-Mee surname: Lim fullname: Lim, Dong-Mee organization: Division of Endocrinology and Metabolism, Department of Internal Medicine, Daejeon 302-832, Korea – sequence: 3 givenname: Hyung-Seo surname: Park fullname: Park, Hyung-Seo organization: Department of Physiology, Konyang University School of Medicine, Daejeon 302-832, Korea – sequence: 4 givenname: Chan-Il surname: Moon fullname: Moon, Chan-Il organization: Department of Cardiology, Gachon University of Medicine and Science, Incheon 406-799, Korea – sequence: 5 givenname: Kyung-Jin surname: Choi fullname: Choi, Kyung-Jin organization: Department of Physiology, Konyang University School of Medicine, Daejeon 302-832, Korea – sequence: 6 givenname: Seong-Kyu surname: Lee fullname: Lee, Seong-Kyu organization: Department of Biochemistry and Molecular Biology, Eulji University School of Medicine, Daejeon 301-746, Korea – sequence: 7 givenname: Haing-Woon surname: Baik fullname: Baik, Haing-Woon organization: Department of Biochemistry and Molecular Biology, Eulji University School of Medicine, Daejeon 301-746, Korea – sequence: 8 givenname: Keun-Young surname: Park fullname: Park, Keun-Young organization: Division of Endocrinology and Metabolism, Department of Internal Medicine, Daejeon 302-832, Korea – sequence: 9 givenname: Byung-Joon surname: Kim fullname: Kim, Byung-Joon email: kbjoon4u@hananet.net organization: Division of Endocrinology and Metabolism, Department of Internal Medicine, Daejeon 302-832, Korea |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22186619$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kctu1DAUhi1URC-wY42ygwUpviWOl6OhhZEqUQlYWyfJydSjjB3spKKvxYP0meoh06wQG9uyP306v_9zcuK8Q0LeMnrJeCE_7Ya7eMkYVfz69gU5Y0KqvCpldbKcmTgl5zHuKOUVZeUrcso5q8qS6TOyuvqNrrUul9lt8CM2Y8xWW7Aujtn3qe-8e-ingJBvXDs12GaPf_I19n22Gvww-mjja_Kygz7im-N-QX5eX_1Yf81vvn3ZrFc3eVNoNeS8FgVWTCrJUUCFLW14R0UtSihbVQiEmle6U5LWVHSouNBNx0FCythCocUF2cze1sPODMHuITwYD9b8vfBhayCMtunRCDyEbgG0lpKLClRZMGBSgK41VSy53s-uIfhfE8bR7G1sUixw6KdoNFOs5EzQRH74L8lFKSk_0An9OKNN8DEG7JYhGTWHqsyhKnOsKuHvjuap3mO7wM_dJODzDOziCFtcgOeUR1tl2LzO3uW5uYNg0CVNOWswlXNvMZjYWHSpSxtS3en37L8HfAIm0LpY |
CitedBy_id | crossref_primary_10_2337_dcS13_2011 crossref_primary_10_3109_10715762_2013_807923 crossref_primary_10_1530_JME_15_0232 crossref_primary_10_2337_db15_0085 crossref_primary_10_1096_fj_202001218R crossref_primary_10_1016_j_tiv_2021_105128 crossref_primary_10_1152_ajpendo_00109_2014 crossref_primary_10_1002_dmrr_2358 crossref_primary_10_1186_s10020_018_0042_5 crossref_primary_10_1111_j_1463_1326_2012_01644_x crossref_primary_10_1007_s13300_012_0012_9 crossref_primary_10_1074_jbc_RA118_005683 crossref_primary_10_1089_dna_2014_2352 crossref_primary_10_1007_s00592_013_0553_z crossref_primary_10_1155_2013_750540 crossref_primary_10_14712_fb2020066050186 crossref_primary_10_1254_jphs_13R10CP crossref_primary_10_1016_j_neuroscience_2012_09_025 crossref_primary_10_1016_j_molmet_2013_12_001 crossref_primary_10_1016_j_jphs_2014_12_007 |
Cites_doi | 10.1006/bbrc.2000.2616 10.1210/jc.2004-0699 10.2165/00024677-200201020-00004 10.1152/ajpcell.1998.274.2.C513 10.1007/s10495-005-3088-0 10.1016/j.coph.2009.07.003 10.1507/endocrj.47.763 10.1385/1-59259-380-1:323 10.1074/jbc.M804184200 10.1016/j.cmet.2006.10.001 10.1177/153537020322801018 10.1016/j.metabol.2006.02.003 10.4093/kdj.2008.32.6.477 10.1016/S0143416002001823 10.1016/S1056-8727(01)00207-0 10.1677/JOE-06-0148 10.4093/kdj.2010.34.1.2 10.2337/diabetes.54.2.452 10.1007/s00441-004-1066-4 10.2174/0929867033456648 10.2337/diabetes.48.10.2001 10.1016/j.ceca.2010.02.001 10.5414/CPP44014 10.1254/jphs.09178FP 10.1016/j.pharmthera.2006.11.007 10.1111/j.1476-5381.2009.00458.x 10.1016/j.diabres.2006.12.021 10.1097/00007890-198612000-00022 10.1042/bj3190521 10.1254/jphs.95.33 10.1152/ajpcell.1995.269.3.C775 10.1016/j.mehy.2008.07.031 10.1210/er.2007-0039 10.2337/diabetes.51.2007.S455 10.1080/09687680010009646 |
ContentType | Journal Article |
Copyright | 2012 Elsevier B.V. The Japanese Pharmacological Society 2011 |
Copyright_xml | – notice: 2012 Elsevier B.V. – notice: The Japanese Pharmacological Society 2011 |
DBID | 6I. AAFTH CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 DOA |
DOI | 10.1254/jphs.11072FP |
DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic Directory of Open Access Journals |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1347-8648 |
EndPage | 74 |
ExternalDocumentID | oai_doaj_org_article_3e8613daa9944238a7651a143a9b9071 10_1254_jphs_11072FP 22186619 article_jphs_118_1_118_11072FP_article_char_en S1347861319305997 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- .55 .GJ 0R~ 0SF 29L 2WC 3O- 4.4 457 53G 5GY 5RE 6I. AACTN AAEDT AAEDW AAFTH AAIKJ AALRI AAXUO ABMAC ACGFO ACGFS ADBBV ADEZE AENEX AEXQZ AFTJW AGHFR AHPSJ AITUG AL- ALMA_UNASSIGNED_HOLDINGS AMRAJ BAWUL BCNDV BKOMP CS3 DIK DU5 E3Z EBS EJD F5P FDB GROUPED_DOAJ GX1 HH5 IPNFZ JMI JSF JSH KQ8 M41 MOJWN M~E NCXOZ O9- OK1 RIG RJT RNS ROL RZJ SSZ TKC TR2 W2D X7M XSB ZGI ZXP AAUGY ADVLN AFJKZ AKRWK CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c597p-2b35e814742e3a8ed0c2f03b36a6d753eab289f740b03fe7239cf2a4a254da593 |
IEDL.DBID | DOA |
ISSN | 1347-8613 |
IngestDate | Tue Oct 22 14:59:49 EDT 2024 Fri Oct 25 01:08:08 EDT 2024 Fri Oct 25 07:01:10 EDT 2024 Thu Sep 26 15:42:36 EDT 2024 Sat Sep 28 08:38:23 EDT 2024 Thu Aug 17 20:29:30 EDT 2023 Fri Feb 23 02:48:52 EST 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | ER stress endoplasmic reticulum (ER) calcium depletion sulfonylurea apoptosis glucagon like peptide-1(GLP-1) |
Language | English |
License | http://creativecommons.org/licenses/by-nc-nd/4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c597p-2b35e814742e3a8ed0c2f03b36a6d753eab289f740b03fe7239cf2a4a254da593 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://doaj.org/article/3e8613daa9944238a7651a143a9b9071 |
PMID | 22186619 |
PQID | 2364027162 |
PQPubID | 23479 |
PageCount | 10 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_3e8613daa9944238a7651a143a9b9071 proquest_miscellaneous_917162130 proquest_miscellaneous_2364027162 crossref_primary_10_1254_jphs_11072FP pubmed_primary_22186619 jstage_primary_article_jphs_118_1_118_11072FP_article_char_en elsevier_sciencedirect_doi_10_1254_jphs_11072FP |
PublicationCentury | 2000 |
PublicationDate | 2012-00-00 |
PublicationDateYYYYMMDD | 2012-01-01 |
PublicationDate_xml | – year: 2012 text: 2012-00-00 |
PublicationDecade | 2010 |
PublicationPlace | Japan |
PublicationPlace_xml | – name: Japan |
PublicationTitle | Journal of Pharmacological Sciences |
PublicationTitleAlternate | J Pharmacol Sci |
PublicationYear | 2012 |
Publisher | Elsevier B.V The Japanese Pharmacological Society Elsevier |
Publisher_xml | – name: Elsevier B.V – name: The Japanese Pharmacological Society – name: Elsevier |
References | 18 Kim JY, Lee SK, Baik HW, Lee KH, Kim HJ, Park KS, et al. Protective effects of glucagon like peptide-1 on HIT-T15 β cell apoptosis via ER stress induced by 2-deoxy-D-glucose. Korean Diabetes J. 2008;32:477–487. 15 Kim MH, Lee MK. The incretins and pancreatic beta-cells: use of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide to cure type 2 diabetes mellitus. Korean Diabetes J. 2010;34:2–9. 13 Holz GG, Chepurny OG. Glucagon-like peptide-1 synthetic analogues: new therapeutic agents for use in the treatment of diabetes mellitus. Curr Med Chem. 2003;10:2471–2483. 29 East JM. Sarco(endo)plasmic reticulum calcium pumps: recent advances in our understanding of structure/function and biology (review). Mol Membr Biol. 2000;17:189–200. 4 Rosak C. The pathophysiologic basis of efficacy and clinical experience with the new oral antidiabetic agents. J Diabetes Complications. 2002;16:123–132. 35 Koh GP, Suh KS, Chon S, Oh SJ, Woo JT, Kim SW, et al. The effect of cAMP-elevating agents on high glucose-induced apoptosis of isolated islets of rat pancreas. Korean Diabetes J. 2004;28:490–500. 6 Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab. 2005;90:501–506. 20 Sutton R, Peters M, McShane P, Gray DW, Morris PJ. Isolation of rat pancreatic islets by ductal injection of collagenase. Transplantation. 1986;42:689–691. 31 Araki E, Oyadomari S, Mori M. Impact of endoplasmic reticulum stress pathway on pancreatic beta-cells and diabetes mellitus. Exp Biol Med (Maywood). 2003;228:1213–1217. 32 Cardozo AK, Ortis F, Storling J, Feng YM, Rasschaert J, Tonnesen M, et al. Cytokines downregulate the sarcoendoplasmic reticulum pump Ca2+ ATPase 2b and deplete endoplasmic reticulum Ca2+, leading to induction of endoplasmic reticulum stress in pancreatic beta-cells. Diabetes. 2005;54:452–461. 34 Yaekura K, Yada T. [Ca2+]i-reducing action of cAMP in rat pancreatic beta-cells: involvement of thapsigargin-sensitive stores. Am J Physiol. 1998;274:C513–C521. 36 Grandoch M, Roscioni SS, Schmidt M. The role of Epac proteins, novel cAMP mediators, in the regulation of immune, lung and neuronal function. Br J Pharmacol. 2010;159:265–284. 24 Inoguchi T, Umeda F, Kakimoto M, Sako Y, Ishii H, Noda K, et al. Chronic sulfonylurea treatment and hyperglycemia aggravate disproportionately elevated plasma proinsulin levels in patients with type 2 diabetes. Endocr J. 2000;47:763–770. 3 Kawaki J, Nagashima K, Tanaka J, Miki T, Miyazaki M, Gonoi T, et al. Unresponsiveness to glibenclamide during chronic treatment induced by reduction of ATP-sensitive K+ channel activity. Diabetes. 1999;48:2001–2006. 14 Doyle ME, Egan JM. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther. 2007;113:546–593. 33 Schildberg FA, Schulz S, Dombrowski F, Minor T. Cyclic AMP alleviates endoplasmic stress and programmed cell death induced by lipopolysaccharides in human endothelial cells. Cell Tissue Res. 2005;320:91–98. 2 Del Prato S, Pulizzi N. The place of sulfonylureas in the therapy for type 2 diabetes mellitus. Metabolism. 2006;55:S20–S27. 7 Takahashi A, Nagashima K, Hamasaki A, Kuwamura N, Kawasaki Y, Ikeda H, et al. Sulfonylurea and glinide reduce insulin content, functional expression of K(ATP) channels, and accelerate apoptotic beta-cell death in the chronic phase. Diabetes Res Clin Pract. 2007;77:343–350. 11 Berridge MJ. The endoplasmic reticulum: a multifunctional signaling organelle. Cell Calcium. 2002;32:235–249. 16 Yusta B, Baggio LL, Estall JL, Koehler JA, Holland DP, Li H, et al. GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress. Cell Metab. 2006;4:391–406. 23 Qian L, Zhang S, Xu L, Peng Y. Endoplasmic reticulum stress in beta cells: latent mechanism of secondary sulfonylurea failure in type 2 diabetes? Med Hypotheses. 2008;71:889–891. 9 Scheuner D, Kaufman RJ. The unfolded protein response: a pathway that links insulin demand with beta-cell failure and diabetes. Endocr Rev. 2008;29:17–33. 17 Tsunekawa S, Yamamoto N, Tsukamoto K, Itoh Y, Kaneko Y, Kimura T, et al. Protection of pancreatic beta-cells by exendin-4 may involve the reduction of endoplasmic reticulum stress; in vivo and in vitro studies. J Endocrinol. 2007;193:65–74. 25 Dworacka M, Abramczyk M, Winiarska H, Kuczynski S, Borowska M, Szczawinska K. Disproportionately elevated proinsulin levels in type 2 diabetic patients treated with sulfonylurea. Int J Clin Pharmacol Ther. 2006;44:14–21. 26 Kim R, Emi M, Tanabe K, Murakami S. Role of the unfolded protein response in cell death. Apoptosis. 2006;11:5–13. 8 Harding HP, Ron D. Endoplasmic reticulum stress and the development of diabetes: a review. Diabetes. 2002;51:S455–S461. 5 Iwakura T, Fujimoto S, Kagimoto S, Inada A, Kubota A, Someya Y, et al. Sustained enhancement of Ca(2+) influx by glibenclamide induces apoptosis in RINm5F cells. Biochem Biophys Res Commun. 2000;271:422–428. 19 Kwon DY, Kim YS, Ahn IS, Kim DS, Kang S, Hong SM, et al. Exendin-4 potentiates insulinotropic action partly via increasing beta-cell proliferation and neogenesis and decreasing apoptosis in association with the attenuation of endoplasmic reticulum stress in islets of diabetic rats. J Pharmacol Sci. 2009;111:361–371. 10 Fonseca SG, Burcin M, Gromada J, Urano F. Endoplasmic reticulum stress in beta-cells and development of diabetes. Curr Opin Pharmacol. 2009;9:763–770. 21 Steensma DP, Timm M, Witzig TE. Flow cytometric methods for detection and quantification of apoptosis. Methods Mol Med. 2003;85:323–332. 28 Wu KD, Lee WS, Wey J, Bungard D, Lytton J. Localization and quantification of endoplasmic reticulum Ca(2+)-ATPase isoform transcripts. Am J Physiol. 1995;269:C775–C784. 22 Park HS, Betzenhauser MJ, Won JH, Chen J, Yule DI. The type 2 inositol (1,4,5)-trisphosphate (InsP3) receptor determines the sensitivity of InsP3-induced Ca2+ release to ATP in pancreatic acinar cells. J Biol Chem. 2008;283:26081–26088. 30 Váradi A, Molnár E, Ostenson CG, Ashcroft SJ. Isoforms of endoplasmic reticulum Ca(2+)-ATPase are differentially expressed in normal and diabetic islets of Langerhans. Biochem J. 1996;319:521–527. 1 Sudhir R, Mohan V. Postprandial hyperglycemia in patients with type 2 diabetes mellitus. Treat Endocrinol. 2002;1:105–116. 12 Sammels E, Parys JB, Missiaen L, De Smedt H, Bultynck G. Intracellular Ca2+ storage in health and disease: a dynamic equilibrium. Cell Calcium. 2010;47:297–314. 27 Sato A, Fujiwara H, Oku H, Ishiguro K, Ohizumi Y. Alpha-mangostin induces Ca2+-ATPase-dependent apoptosis via mitochondrial pathway in PC12 cells. J Pharmacol Sci. 2004;95:33–40. 22 23 24 25 26 27 28 29 31 10 32 11 33 12 34 13 35 14 36 15 16 17 (30) 1996; 319 18 19 1 2 3 4 5 6 7 8 9 20 21 |
References_xml | – ident: 5 doi: 10.1006/bbrc.2000.2616 – ident: 6 doi: 10.1210/jc.2004-0699 – ident: 1 doi: 10.2165/00024677-200201020-00004 – ident: 34 doi: 10.1152/ajpcell.1998.274.2.C513 – ident: 35 – ident: 26 doi: 10.1007/s10495-005-3088-0 – ident: 10 doi: 10.1016/j.coph.2009.07.003 – ident: 24 doi: 10.1507/endocrj.47.763 – ident: 21 doi: 10.1385/1-59259-380-1:323 – ident: 22 doi: 10.1074/jbc.M804184200 – ident: 16 doi: 10.1016/j.cmet.2006.10.001 – ident: 31 doi: 10.1177/153537020322801018 – ident: 2 doi: 10.1016/j.metabol.2006.02.003 – ident: 18 doi: 10.4093/kdj.2008.32.6.477 – ident: 11 doi: 10.1016/S0143416002001823 – ident: 4 doi: 10.1016/S1056-8727(01)00207-0 – ident: 17 doi: 10.1677/JOE-06-0148 – ident: 15 doi: 10.4093/kdj.2010.34.1.2 – ident: 32 doi: 10.2337/diabetes.54.2.452 – ident: 33 doi: 10.1007/s00441-004-1066-4 – ident: 13 doi: 10.2174/0929867033456648 – ident: 3 doi: 10.2337/diabetes.48.10.2001 – ident: 12 doi: 10.1016/j.ceca.2010.02.001 – ident: 25 doi: 10.5414/CPP44014 – ident: 19 doi: 10.1254/jphs.09178FP – ident: 14 doi: 10.1016/j.pharmthera.2006.11.007 – ident: 36 doi: 10.1111/j.1476-5381.2009.00458.x – ident: 7 doi: 10.1016/j.diabres.2006.12.021 – ident: 20 doi: 10.1097/00007890-198612000-00022 – volume: 319 start-page: 521 issn: 0264-6021 issue: 2 year: 1996 ident: 30 doi: 10.1042/bj3190521 – ident: 27 doi: 10.1254/jphs.95.33 – ident: 28 doi: 10.1152/ajpcell.1995.269.3.C775 – ident: 23 doi: 10.1016/j.mehy.2008.07.031 – ident: 9 doi: 10.1210/er.2007-0039 – ident: 8 doi: 10.2337/diabetes.51.2007.S455 – ident: 29 doi: 10.1080/09687680010009646 |
SSID | ssj0028016 |
Score | 2.130456 |
Snippet | Sulfonylurea is one of the commonly used anti-diabetic drugs that stimulate insulin secretion from β-cells. Despite their glucose lowering effects in type 2... |
SourceID | doaj proquest crossref pubmed jstage elsevier |
SourceType | Open Website Aggregation Database Index Database Publisher |
StartPage | 65 |
SubjectTerms | Animals apoptosis Apoptosis - drug effects Calcium - metabolism Cell Line Cricetinae endoplasmic reticulum (ER) calcium depletion Endoplasmic Reticulum - drug effects Endoplasmic Reticulum - metabolism Endoplasmic Reticulum Stress - drug effects ER stress Exenatide glucagon like peptide-1(GLP-1) Glucagon-Like Peptide 1 - agonists Glyburide - adverse effects Hypoglycemic Agents - adverse effects Insulin-Secreting Cells - drug effects Insulin-Secreting Cells - metabolism Peptides - pharmacology Rats Rats, Sprague-Dawley sulfonylurea Venoms - pharmacology |
Title | Exendin-4 Protects Against Sulfonylurea-Induced β-Cell Apoptosis |
URI | https://dx.doi.org/10.1254/jphs.11072FP https://www.jstage.jst.go.jp/article/jphs/118/1/118_11072FP/_article/-char/en https://www.ncbi.nlm.nih.gov/pubmed/22186619 https://search.proquest.com/docview/2364027162 https://search.proquest.com/docview/917162130 https://doaj.org/article/3e8613daa9944238a7651a143a9b9071 |
Volume | 118 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
ispartofPNX | Journal of Pharmacological Sciences, 2012, Vol.118(1), pp.65-74 |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3BTtwwELUQp15QCy1NKciVKCesTWzHax84bBErhNRqJUDiZtnJhC5Cu1GzK8Fv8SF8E-M4Wcph1UsvOSSObc3YnvcS-w0hhx4HgQCTM11UKZM-z5gWpWKZwpkHHLRu86f8_KXOr-XFTX7zV6qvsCcsygNHww0EaIw4pXPGSAz92g1VnjmM8s54JHaR-KSmJ1Md1cJ1tz1XJCSuwfh-t-Ud2dDgrv7dhM3vQ17Vb4JRq9n_NibdIUK7hfXgsw1C4_dkq0OPdBR7_YFswGybHE2i_PTjMb16PU3VHNMjOnkVpn7cIaOzBwiHWJikkyjP0NDRrZsiQqSXy_uq36TOQj6PAkr6_MRO4R7bq-f1Yt5Mm4_kenx2dXrOuhQKrECmUDPuRQ46k0iAQTgNZVrwKhVeKKdKZCrgPDKuaihTn4oKhlyYouJOOrRU6XIjPpHN2XwGnwkNWE4UQY1eOVmpwnvFS-kKZzLtETcm5HtvS1tHpQwbGAbWZIPNbWvz8SQhP4KhV2WCvnV7A71uO6_bf3k9IYPeTbaDChECYFXTNc2eRG-uGu7b6kppm8VrLL96HE6_4RKSkG_9ILA4A8NvFTeD-bKxQYIfyX2meELomjImqBJxxAsJ2Y0DaNUNHrKCIY398j_sskfeIaLj8RvRV7K5-LOEfURNC3_QTpCDELnyFx76ErY |
link.rule.ids | 315,783,787,867,2109,4031,27935,27936,27937 |
linkProvider | Directory of Open Access Journals |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Exendin-4+protects+against+sulfonylurea-induced+%CE%B2-cell+apoptosis&rft.jtitle=Journal+of+pharmacological+sciences&rft.au=Kim%2C+Ju-Young&rft.au=Lim%2C+Dong-Mee&rft.au=Park%2C+Hyung-Seo&rft.au=Moon%2C+Chan-Il&rft.date=2012&rft.eissn=1347-8648&rft.volume=118&rft.issue=1&rft.spage=65&rft.epage=74&rft_id=info:doi/10.1254%2Fjphs.11072fp&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1347-8613&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1347-8613&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1347-8613&client=summon |